OncoMatch/Clinical Trials/NCT07086105
A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma
Is NCT07086105 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies Adze1.C for metastatic melanoma.
Treatment: Adze1.C — This is Phase I, open label, multi-center clinical trial evaluating an investigational treatment, Adze1.C. Adze1.C is a type of oncolytic virus therapy for adults with advanced Melanoma that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potential to stimulate the immune system to fight tumors. The purpose of this study is to assess preliminary efficacy, determine the safety of Adze1.C, how well it is tolerated, and to identify the highest dose that can be safely given.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Melanoma
Disease stage
Required: Stage IIIB, IIIC, IIID, IV
Metastatic disease required
unresectable Stage IIIB to IV metastatic melanoma
Performance status
ECOG 0–1(Restricted strenuous activity)
ECOG performance status of 0 or 1 at Screening
Prior therapy
Cannot have received: adenovirus therapy
Lab requirements
Liver function
Active or clinically significant liver disease, including: Hepatitis B surface antigen (HBsAg) positive; Hepatitis C virus RNA positive
Cardiac function
Symptomatic congestive heart failure; NYHA Class III or IV heart failure; Unstable angina or arrhythmia
Active or clinically significant liver disease, including: Hepatitis B surface antigen (HBsAg) positive; Hepatitis C virus RNA positive. Symptomatic congestive heart failure; NYHA Class III or IV heart failure; Unstable angina or arrhythmia
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07086105 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior adenovirus therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage IIIB or IIIC or IIID or IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages